Events
The Jefferies Global Healthcare Conference, London
16-19 November, 2026
London, UK
ENYO Pharma is attending The Jefferies Global Healthcare Conference on November 16-19, 2026, in London, engaging with venture investors to discuss near‑ and mid‑term value‑creation across our kidney disease pipeline. It is a great opportunity to share our progress with Vonafexor and its fast follower EYP651, both FXR agonists with anti-inflammatory and fibrolytic properties, developed for kidney diseases.
https://www.jefferies.com/events/global-healthcare-conference-in-london-2/
ASN – the American Society of Nephrology 2026
21-25 October 2026
Denver, Colorado
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN. During the meeting, our team will engage with the nephrology and investment communities to discuss our rare kidney disease program, including Vonafexor and its follow-on compound, EYP651.
The 2026 International Workshop on Alport Syndrome
5-7 September 2026
Budapest, Hungary
ENYO Pharma will attend The 2026 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.
ENYO Pharma will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients, with a poster titled “Vonafexor Stabilizes the Rapid eGFR Decline in Progressive Alport Syndrome: Results from the Phase 2 ALPESTRIA-1 Trial”.
Alport Connect 2026, the annual Alport syndrome patient and family meeting in US
18-19 July 2026
Philadelphia
ENYO Pharma is sponsoring and will attend Alport Connect 2026 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.
ENYO Pharma will meet patients and their families to present the results of the Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
Alport Research Hub Symposium 2026, London
03 July 2026
London, UK
ENYO Pharma will attend the third annual symposium of the Alport Research Hub organized by Alport UK association.
ENYO Pharma will meet patients and their families and present the results of the Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients: “Vonafexor: Phase 2 Efficacy and Safety Results in Progressive Alport Syndrome
Latest Press Release 